Praxis Precision Medicines, Inc. PRAX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-16
Chart by TradingView
2/9
Piotroski F — financial health
12.98
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$9.1B
P / B10.4×
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $8.6M | $2.4M | $0 | — |
| Operating income | -$326.2M | -$200.2M | -$126.4M | -$215.0M | -$167.3M |
| Net income | -$303.3M | -$182.8M | -$123.3M | -$214.0M | -$167.1M |
| Operating cash flow | -$249.1M | -$131.8M | -$111.1M | -$185.0M | -$124.6M |
| Free cash flow | -$249.1M | -$131.8M | -$111.2M | -$185.5M | -$125.6M |
| Total assets | $937.9M | $483.1M | $87.9M | $115.1M | $292.7M |
| Total liabilities | $59.8M | $37.7M | $18.3M | $39.0M | $41.9M |
| Shareholders' equity | $878.1M | $445.4M | $69.7M | $76.1M | $250.8M |
| Ratios | |||||
| Operating margin | — | -2340.3% | -5164.4% | — | — |
| Net margin | — | -2137.5% | -5037.9% | — | — |
| FCF margin | — | -1540.5% | -4543.8% | — | — |
| Return on assets | -32.3% | -37.8% | -140.2% | -185.9% | -57.1% |
| Return on equity | -34.5% | -41.0% | -176.9% | -281.2% | -66.6% |
| Current ratio | 10.22 | 10.77 | 5.39 | 3.23 | 7.48 |
| Revenue growth | -100.0% | 249.5% | — | — | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 12.98 (safe)
- Working capital / assets 0.588
- Retained earnings / assets -1.215
- EBIT / assets -0.348
- Equity / liabilities 14.692
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001689548 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.